Are Combinations the Answer in Metastatic RCC?

Adjuvant pembrolizumab had an estimated 91.2% overall survival rate after 4 years compared with 86.0% for patients with clear-cell renal cell carcinoma who received a placebo.

In this episode of Emerging Experts, Nazli Dizman, MD, shares the intricacies of her journey towards becoming an oncologist in the United States.

A new study found that Black patients with prostate cancer were less likely to get new treatments and had a higher risk of death than White patients.

In this episode of Emerging Experts, Peter Zang, MD, highlights research on baseline CD8 lymph node avidity with 89-Zr-crefmirlimab for the treatment of patients with metastatic renal cell carcinoma and response to immunotherapy.

A real-world study found adding a PD-L1 inhibitor to cabozantinib offered no significant survival advantage for patients with metastatic kidney cancer who had already received a PD-L1 inhibitor.

The novel PPAR-α inhibitor TPST-1120 shows promise for solid tumors, including renal cell carcinoma, as monotherapy and in combination with nivolumab.